417 related articles for article (PubMed ID: 24953712)
1. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta.
Roschger A; Roschger P; Keplingter P; Klaushofer K; Abdullah S; Kneissel M; Rauch F
Bone; 2014 Sep; 66():182-8. PubMed ID: 24953712
[TBL] [Abstract][Full Text] [Related]
2. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
[TBL] [Abstract][Full Text] [Related]
3. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta.
Sinder BP; Eddy MM; Ominsky MS; Caird MS; Marini JC; Kozloff KM
J Bone Miner Res; 2013 Jan; 28(1):73-80. PubMed ID: 22836659
[TBL] [Abstract][Full Text] [Related]
4. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
[TBL] [Abstract][Full Text] [Related]
5. Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.
Olvera D; Stolzenfeld R; Marini JC; Caird MS; Kozloff KM
J Bone Miner Res; 2018 Jul; 33(7):1272-1282. PubMed ID: 29544018
[TBL] [Abstract][Full Text] [Related]
6. Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.
Sinder BP; Lloyd WR; Salemi JD; Marini JC; Caird MS; Morris MD; Kozloff KM
Bone; 2016 Mar; 84():222-229. PubMed ID: 26769006
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone injections improve bone quality in a mouse model of osteogenesis imperfecta.
King D; Jarjoura D; McEwen HA; Askew MJ
J Bone Miner Res; 2005 Jun; 20(6):987-93. PubMed ID: 15883639
[TBL] [Abstract][Full Text] [Related]
8. Effect of sclerostin inactivation in a mouse model of severe dominant osteogenesis imperfecta.
Marulanda J; Tauer JT; Boraschi-Diaz I; Bardai G; Rauch F
Sci Rep; 2023 Mar; 13(1):5010. PubMed ID: 36973504
[TBL] [Abstract][Full Text] [Related]
9. Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/+ osteogenesis imperfecta model.
Perosky JE; Khoury BM; Jenks TN; Ward FS; Cortright K; Meyer B; Barton DK; Sinder BP; Marini JC; Caird MS; Kozloff KM
Bone; 2016 Dec; 93():79-85. PubMed ID: 27641475
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1(+/mov13) mouse model of type I Osteogenesis Imperfecta.
Jacobsen CM; Schwartz MA; Roberts HJ; Lim KE; Spevak L; Boskey AL; Zurakowski D; Robling AG; Warman ML
Bone; 2016 Sep; 90():127-32. PubMed ID: 27297606
[TBL] [Abstract][Full Text] [Related]
11. Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.
Little DG; Peacock L; Mikulec K; Kneissel M; Kramer I; Cheng TL; Schindeler A; Munns C
Bone; 2017 Aug; 101():96-103. PubMed ID: 28461254
[TBL] [Abstract][Full Text] [Related]
12. Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta.
Cardinal M; Tys J; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
Bone; 2019 Jul; 124():137-147. PubMed ID: 31051315
[TBL] [Abstract][Full Text] [Related]
13. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.
Cardinal M; Dessain A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
Calcif Tissue Int; 2020 May; 106(5):494-508. PubMed ID: 32025752
[TBL] [Abstract][Full Text] [Related]
14. Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy.
Nicol L; Wang Y; Smith R; Sloan J; Nagamani SC; Shapiro J; Lee B; Orwoll E
J Bone Miner Res; 2018 Feb; 33(2):307-315. PubMed ID: 29044725
[TBL] [Abstract][Full Text] [Related]
15. Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta.
Grafe I; Alexander S; Yang T; Lietman C; Homan EP; Munivez E; Chen Y; Jiang MM; Bertin T; Dawson B; Asuncion F; Ke HZ; Ominsky MS; Lee B
J Bone Miner Res; 2016 May; 31(5):1030-40. PubMed ID: 26716893
[TBL] [Abstract][Full Text] [Related]
16. Effect of Anti-TGF-β Treatment in a Mouse Model of Severe Osteogenesis Imperfecta.
Tauer JT; Abdullah S; Rauch F
J Bone Miner Res; 2019 Feb; 34(2):207-214. PubMed ID: 30357929
[TBL] [Abstract][Full Text] [Related]
17. Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta.
Boraschi-Diaz I; Chen G; Polak-Nachumow J; Young RN; Rauch F
Bone; 2021 Apr; 145():115867. PubMed ID: 33524637
[TBL] [Abstract][Full Text] [Related]
18. Conditional Deletion of Sost in MSC-Derived Lineages Identifies Specific Cell-Type Contributions to Bone Mass and B-Cell Development.
Yee CS; Manilay JO; Chang JC; Hum NR; Murugesh DK; Bajwa J; Mendez ME; Economides AE; Horan DJ; Robling AG; Loots GG
J Bone Miner Res; 2018 Oct; 33(10):1748-1759. PubMed ID: 29750826
[TBL] [Abstract][Full Text] [Related]
19. Correlations Between Bone Mechanical Properties and Bone Composition Parameters in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-TGF-β Treatment.
Bi X; Grafe I; Ding H; Flores R; Munivez E; Jiang MM; Dawson B; Lee B; Ambrose CG
J Bone Miner Res; 2017 Feb; 32(2):347-359. PubMed ID: 27649409
[TBL] [Abstract][Full Text] [Related]
20. Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.
Jeong Y; Daghlas SA; Xie Y; Hulbert MA; Pfeiffer FM; Dallas MR; Omosule CL; Pearsall RS; Dallas SL; Phillips CL
J Bone Miner Res; 2018 Oct; 33(10):1760-1772. PubMed ID: 29813187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
